DPH N Stock Overview Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Dechra Pharmaceuticals PLC Competitors Price History & Performance
Summary of share price highs, lows and changes for Dechra Pharmaceuticals Historical stock prices Current Share Price UK£858.69 52 Week High UK£863.85 52 Week Low UK£740.83 Beta 0.71 1 Month Change 0% 3 Month Change n/a 1 Year Change 2.09% 3 Year Change 34.09% 5 Year Change n/a Change since IPO 28.77%
Recent News & Updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP) See more updates Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 20
Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million. Jul 18
Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million. Apr 12 Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH). Jan 17
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)
Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024 Dec 27
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 29
Dechra Pharmaceuticals Plc Announces Directorate Change Nov 28
Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023 Sep 27 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director Jun 17
Dechra Pharmaceuticals Intends to Delist from Official List Jun 03
Less than half of directors are independent Jan 31
Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company Dec 21
Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index Dec 19 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023
Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022 Sep 05
Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis. Aug 31 Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.
Less than half of directors are independent Jun 13
Investor sentiment improved over the past week May 24
Dechra Pharmaceuticals PLC Announces Executive Changes May 18
Investor sentiment deteriorated over the past week Apr 29
Less than half of directors are independent Apr 28
Investor sentiment improved over the past week Apr 12
Non-Executive Chairman recently bought Mex$2.6m worth of stock Apr 09
Investor sentiment improved over the past week Mar 23
First half 2022 earnings: Revenues and EPS in line with analyst expectations Feb 23
Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022 Feb 22
Dechra Pharmaceuticals plc Announces Executive Changes Feb 17
Investor sentiment deteriorated over the past week Jan 27
Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc. Jan 12 Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)
Non-Executive Director Denise Goode has left the company Dec 01
Less than half of directors are independent Nov 22
Upcoming dividend of UK£0.29 per share Oct 22
Less than half of directors are independent Oct 22
Non-Executive Director recently bought Mex$178k worth of stock Sep 11
Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020) Sep 07
Less than half of directors are independent Aug 04
Board Member recently sold Mex$27m worth of stock Apr 17
Non-Executive Director recently bought Mex$587k worth of stock Mar 13
Non-Executive Director recently bought Mex$587k worth of stock Mar 12
First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020) Feb 23
Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C Feb 10 Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021
CEO, MD & Executive Director recently sold Mex$279m worth of stock Nov 22
Dechra Pharmaceuticals PLC Launches Mirataz Nov 10
Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021 Oct 27
Non-Executive Director recently bought Mex$712k worth of stock Oct 08
Independent Non Executive Director recently sold Mex$3.5m worth of stock Sep 23 Shareholder Returns DPH N MX Pharmaceuticals MX Market 7D 0% -1.1% -0.8% 1Y 2.1% -18.0% -13.5%
See full shareholder returns
Return vs Market: DPH N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility Is DPH N's price volatile compared to industry and market? DPH N volatility DPH N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.8% Market Average Movement 4.0% 10% most volatile stocks in MX Market 6.8% 10% least volatile stocks in MX Market 2.7%
Stable Share Price: DPH N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DPH N's volatility change over the past year.
About the Company Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
Show more Dechra Pharmaceuticals PLC Fundamentals Summary How do Dechra Pharmaceuticals's earnings and revenue compare to its market cap? DPH N fundamental statistics Market cap Mex$95.37b Earnings (TTM ) Mex$902.94m Revenue (TTM ) Mex$16.37b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DPH N income statement (TTM ) Revenue UK£726.80m Cost of Revenue UK£312.20m Gross Profit UK£414.60m Other Expenses UK£374.50m Earnings UK£40.10m
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Sep 04, 2023
Earnings per share (EPS) 0.35 Gross Margin 57.04% Net Profit Margin 5.52% Debt/Equity Ratio 61.8%
How did DPH N perform over the long term?
See historical performance and comparison Dividends
1.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/04/28 08:36 End of Day Share Price 2023/01/29 00:00 Earnings 2022/12/31 Annual Earnings 2022/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Dechra Pharmaceuticals PLC is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Laurent Gelebart BNP Paribas Exane Brian White Cantor Fitzgerald Europe
Show 18 more analysts 
